Videos

Panelists discuss how delayed-release/extended-release amantadine represents a unique treatment option for patients like the 54-year-old woman with both dyskinesia and “off” time, as it is the only FDA-approved medication that addresses both conditions simultaneously, with its bedtime dosing and pharmacokinetic profile providing overnight absorption and sustained daytime levels that resulted in phase 3 trials showing a 40% reduction in dyskinesia and 2.4 hours of increased good “on” time, making it an ideal first-line treatment for patients who have both troublesome dyskinesia and motor fluctuations rather than simply reducing dopaminergic medications which would worsen motor symptoms.

Panelists discuss how obstructive sleep apnea affects potentially up to 1 billion people globally, with excessive daytime sleepiness being a common but often underreported presenting complaint that patients may not recognize or admit to experiencing.

In this segment, Eric Olson, MD, and Anita Shelgikar, MD, discuss the design of the Vibrance-3 trial, a phase 2 study of the orexin-2 receptor agonist ALKS 2680 in patients with idiopathic hypersomnia. [WATCH TIME: 4 minutes]

In episode 3, Drs. Olson and Shelgikar break down a retrospective study exploring how social determinants of health impact the clinical experience of patients with narcolepsy. [WATCH TIME: 6 minutes]

Neurology News Network. for the week ending July 26, 2025. [WATCH TIME: 4 minutes]

Panelists Eric Olson, MD, and Anita Shelgikar, MD, examine interim data on high-dose low-sodium oxybate in patients with narcolepsy, discussing safety signals, efficacy trends, and clinical considerations. [WATCH TIME: 4 minutes]

A panelist discusses the importance of obtaining a comprehensive sleep history before prescribing medication for chronic insomnia and highlights the growing role of dual orexin receptor antagonists as a safer, first-line treatment option with fewer adverse effects compared with older sleep medications like benzodiazepines.

The postdoctoral neuropsychology fellow at North Shore University Hospital talked about recognizing and aligning subjective cognitive complaints with objective assessments in patients with migraine during the interictal period. [WATCH TIME: 6 minutes]

In this episode, Eric Olson, MD, and Anita Shelgikar, MD, review the XYLO study’s findings on the impact of switching from high- to low-sodium oxybate on blood pressure in patients with narcolepsy.

The chief program officer at PMD Alliance described an interactive program designed to help health care providers better understand the lived experience of patients with Parkinson disease and related movement disorders. [WATCH TIME: 6 minutes]

The head of medical development for donanemab at Eli Lilly and Company explained how donanemab’s modified titration dosing regimen could reduce ARIA risk and improve clinical decision-making following the drug’s FDA label update. [WATCH TIME: 3 minutes]

The head of medical development for donanemab at Eli Lilly and Company provided insights on the structure of TRAILBLAZER-ALZ 6, a study comparing numerous different dosing regimens of donanemab. [WATCH TIME: 3 minutes]

Panelists discuss how a 54-year-old woman with early-onset Parkinson disease presenting with troublesome peak-dose dyskinesia affecting her work performance illustrates the challenge of managing patients who have both dyskinesia and likely OFF episodes, requiring careful assessment of functional impacts through targeted questioning about daily activities, work performance, and social interactions, since patients often minimize or remain unaware of their dyskinesia's true impact while caregivers may provide crucial insights into how the involuntary movements affect not only the patient but also family dynamics and professional relationships.

A duo of experts discussed a novel hybrid trial approach combining in-home video assessments with traditional visits to improve Parkinson disease research participation and assess a new investigational therapy. [WATCH TIME: 7 minutes]

Panelists discuss how dyskinesia affects 30% to 50% of Parkinson patients by 5 years and over 90% by 10 years, creating significant functional limitations including impaired writing, eating, and dressing abilities, increased fall risk, job performance challenges, social isolation due to embarrassment about abnormal movements, and restrictions on therapeutic options since increasing levodopa doses to manage OFF time would worsen dyskinesia, ultimately impacting both patients' basic human dignity and their caregivers' quality of life.

The professor of neurology at Thomas Jefferson University discussed the shifting diagnostic challenges of stiff person syndrome and reviewed current and emerging treatment options. [WATCH TIME: 6 minutes]

The associate professor of neurology at Johns Hopkins detailed how artificial intelligence is shaping the future of neurology through its integration in clinical care, research, and medical education. [WATCH TIME: 4 minutes]

Neurology News Network. for the week ending July 19, 2025. [WATCH TIME: 4 minutes]

At AHS 2025, the assistant professor of neurology at the Icahn School of Medicine at Mount Sinai highlighted the challenges LGBTQIA+ individuals may face in migraine care. [WATCH TIME: 6 minutes]

The assistant professor of neurology at Wake Forest Baptist Atrium Health discussed emerging research on how breast size may contribute to headache disorders, including migraine. [WATCH TIME: 5 minutes]

A panelist discusses the use of dual orexin receptor antagonists as a first-line treatment for chronic insomnia due to their efficacy in improving sleep without the risks of dependence or cognitive issues, while also noting their effectiveness in patients with psychophysiologic insomnia and the importance of managing patient expectations regarding their use.

The professor of neurology at the University of Miami Miller School of Medicine provided context on the clinical use of the Cognivue Amyloid Risk Measure in the context of Alzheimer disease care. [WATCH TIME: 3 minutes]

The professor of neuroscience at Harvard Medical School highlighted gaps in headache care access, provider training, and medication availability in regions like Kenya and the Philippines. [WATCH TIME: 5 minutes]

The director of sleep health at Flinders University in Australia explored how combination pharmacologic and noninvasive therapies may offer a personalized path forward in obstructive sleep apnea treatment. [WATCH TIME: 6 minutes]

Nuri Jacoby, MD, a neurologist at Maimonides Medical Center and SUNY Downstate, previewed his talk at the 2025 AUPN Annual Meeting on using simulation to evaluate nonclinical competencies like communication and professionalism. [WATCH TIME: 3 minutes]

The professor of neurological surgery at Weill Cornell Medicine shared his reaction to the recent approval of the Exablate Neuro platform that uses MRI-guided focused ultrasound to treat Parkinson disease. [WATCH TIME: 5 minutes]

The associate professor of medicine at the Icahn School of Medicine at Mount Sinai outlined emerging interventions aimed at enhancing glymphatic clearance to potentially lower Alzheimer disease risk. [WATCH TIME: 4 minutes]

Panelists discuss how newer Parkinson disease therapies may impact dyskinesia management by potentially providing continuous dopaminergic stimulation that could prevent dyskinesia development if used early, though current evidence from phase 3 trials shows mixed results with improvements in good ON time (ON time without troublesome dyskinesia) but limited reduction in existing troublesome dyskinesia, suggesting that while these treatments offer promise, more research is needed to determine their effectiveness in reducing dyskinesia in patients who already experience it.

Panelists discuss how recent advancements in Parkinson disease treatment include 3 newly approved medications—an oral extended-release carbidopa-levodopa with mucoadhesive properties, a subcutaneous foslevodopa infusion, and a subcutaneous apomorphine infusion—that aim to provide more continuous dopamine stimulation and reduce motor fluctuations by offering longer-lasting benefits and smoother symptom control compared with traditional immediate-release formulations.

The movement disorder specialist and patient living with Parkinson disease highlighted the need for a more human-centered approach in managing chronic and progressive movement disorders. [WATCH TIME: 6 minutes]